We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Human Granulocytic Anaplasmosis Confirmed by Molecular Assay

By LabMedica International staff writers
Posted on 26 Mar 2012
Human granulocytic anaplasmosis (HGA) is a tick-borne infection, yet few clinical cases have been diagnosed by a positive polymerase chain reaction (PCR) assay. More...


Subsequent seroconversion against the antigen of the causative intraerythrocytic agent, Anaplasma phagocytophilum, would fulfill the epidemiologic, clinical, and biological criteria for HGA, which is characterized by an acute, nonspecific febrile illness.

At the Hôpitaux Universitaires de Strasbourg (France), 15 patients presented with a febrile syndrome with a recent history of tick bites or exposures to ticks were tested for HGA, during the period June to September 2009. Whole blood samples with ethylenediaminetetraacetic acid (EDTA) were systematically collected for blood smear and specific PCR assay during the febrile phase of the disease. For serologic testing, two sera were also collected: the first during the acute phase and the second two to three weeks afterwards, during the convalescent phase.

DNA was extracted from whole-blood samples and real-time PCR was performed on the ABI Prism 7000 SDS (Applied Biosystems; Foster City, CA, USA). Serologic diagnosis of infection with A. phagocytophilum was made by immunofluorescent antibody test (IFA) (Focus Diagnostics, Cypress, CA, USA). Serum specimens with immunoglobulin M (IgM) titers of equal or greater than 1:40 and IgG titers equal to or greater than 1:64 were considered positive. Blood smears were obtained from whole blood samples, stained with May-Grünwald-Giemsa and examined for the presence of morulae within the cytoplasm of neutrophils

Molecular testing using the major surface protein 2 (msp2)/p44 gene yielded positive results in the acute-phase blood of three of the 15 patients tested. For the 12 patients with negative PCR assay, microscopic examination was negative and no specific antibodies were detected in acute-phase serum. Laboratory findings were available for 6 patients among the 12 with a negative PCR assay; all these 6 presented leucopenia, thrombocytopenia, and increased levels of liver enzymes. For the three patients with positive PCR results, examination of peripheral blood smears revealed cytoplasmic inclusions suggestive of A. phagocytophilum morulae and elevated serum levels of liver enzymes.

The authors concluded that a specific PCR assay on EDTA anticoagulated blood may be the diagnostic test of choice for HGA during the first two weeks following the onset of symptoms, allowing a faster diagnosis than serology. HGA should be included in the differential diagnosis of patients presenting febrile illness associated with bicytopenia, elevated rates of liver enzymes, increased C-reactive protein values, and whose medical history reveals recent exposure to ticks. The study was published in the March 2012 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Hôpitaux Universitaires de Strasbourg
Applied Biosystems
Focus Diagnostics



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.